Abstract
Is modified FOLFIRINOX a standard regimen for 2nd line chemotherapy for pancreatic cancer after gemcitabine plus nab-paclitaxel failure?—insights from the MPACA-3 trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have